Prithviraj Bose, MD

All articles by Prithviraj Bose, MD

Venetoclax and ibrutinib are therapeutic agents for CLL.

Expert Perspective: The Role of Ibrutinib and Venetoclax in Chronic Lymphocytic Leukemia

By

Prithviraj Bose, MD

January 10, 2019

Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.

Next post in ASH 2018

Insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.

Advances in Treatment and Prevention of Hemophilia A: Takeaways From the 2018 ASH Annual Meeting